Peer-Reviewed Journal Details
Mandatory Fields
Vanoirbeek, E;Eelen, G;Verlinden, L;Carmeliet, G;Mathieu, C;Bouillon, R;O'Connor, R;Xiao, G;Verstuyf, A
2014
April
Oncogene
PDLIM2 expression is driven by vitamin D and is involved in the pro-adhesion, and anti-migration and -invasion activity of vitamin D
Validated
Optional Fields
DOMAIN-CONTAINING PROTEIN-2 1,25-DIHYDROXYVITAMIN D-3 BREAST-CANCER PROSTATE-CANCER TARGET GENES CELLS DNA 1-ALPHA,25-DIHYDROXYVITAMIN-D-3 IDENTIFICATION METHYLATION
33
1904
1911
1Alpha, 25-dihydroxyvitamin D-3[1,25(OH)(2)D-3], the biologically active form of vitamin D-3, is a pleiotropic hormone that exerts its effects on a wide range of tissues, resulting in different biological responses such as anticancer activity. It is the ligand of the vitamin D receptor (VDR), a nuclear receptor with transactivating capacity. We demonstrated in this study that 1,25(OH)(2)D-3 induces PDZ-LIM domain-containing protein 2 (PDLIM2) expression. PDLIM2 is an adaptor molecule that links different components of the cytoskeleton, and was recently shown to be repressed in human breast cancer cells by hypermethylation of regulatory promoter regions, leading to enhanced tumorigenicity. We demonstrated that PDLIM2 was a direct target gene of 1,25(OH)(2)D-3; its upregulation was VDR-dependent and a functional VDRE in the promoter was identified. Moreover, 1,25(OH)(2)D-3 induced demethylation of the PDLIM2 promoter, leading to enhanced transcription. Finally, PDLIM2 was found to be crucial for 1,25(OH)(2)D-3-induced cell adhesion and for mediating the ability of 1,25(OH)(2)D-3 to suppress cancer cell migration and invasion. This study provides mechanistic insights into the anticancer activities of 1,25(OH)(2)D-3 in human breast cancer cells.
LONDON
0950-9232
10.1038/onc.2013.123
Grant Details